Next-generation biotech with radical AI software designed to minimize drug discovery risks and costs by up to 80%.
Ainnocence, founded in 2021 in Bay Area, California, is a next-generation biotech company with a radical AI software system designed to minimize drug discovery risks and costs by up to 80%. Its fast-evolving platform delivers lightning-fast virtual screening and multi-objective pharmacological optimization for small molecules, antibodies, and other complex therapeutic modalities.
With a computational capacity to screen up to 10 Billion protein sequences or chemical compounds within hours, Ainnocence significantly reduces discovery time and costs while achieving exceptionally high wet-lab hit rates. The AI system enables drug design to tackle previously undruggable or 3D structure unknown targets to achieve a 75% expanded therapeutic space.
Our groundbreaking AI system empowers biotech and pharmaceutical companies to boldly pursue ambitious 'moonshot' cures, reshaping the future of R&D by accelerating the discovery of life-saving therapies with unprecedented speed, lower costs, and higher success rates.
Our Name
Primum non nocere — first, do no harm — is medicine's oldest commitment. It is also, literally, what our name means: innocence comes from the Latin in-nocens, not harming.
We design molecules that go into people. That obligation shapes how we work: we report the wet-lab result for every design, including the ones that failed; we publish benchmarks that make our own numbers harder to beat; and we screen what we are asked to design.
Values
Ainnocence is AI in service of medicine's first obligation: do no harm. Our platform is designed to accelerate discovery while keeping evidence, safety, and human responsibility at the center of every molecule we help create.
We screen what we are asked to design and treat downstream patient impact as a design constraint, not an afterthought.
We report wet-lab results for every design, including failures, so partners can judge the real performance of the platform.
We publish benchmarks that make our own numbers harder to beat, because credibility depends on tests that resist easy wins.
AI can propose, rank, and optimize, but responsibility stays with the scientists, clinicians, and partners making decisions for people.
We envision AI as a catalyst for innovation, driving a better world through transformative advancements in healthcare. Our mission is to make precision medicine accessible, not aspirational.
809 Cuesta Dr Suite B #1147
Mountain View, CA 94040
info@ainnocence.com